Currently running clinical trials assess the efficacy of selective, oral c-MET inhibitor tivantinib (ARQ 197), capmatinib (INC280), and anti-HGF antibody ficlatuzumab (AV-299) in patients with recurrent, metastatic HNSCC after progression on cetuximab or panitumumab therapy (NCT01696955, NCT02205398, and NCT03422536). The gene discussed is HGF; the disease is head and neck squamous cell carcinoma.